Literature DB >> 16446155

Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652.

Rona S Duncan1, John M Ridley, Christopher E Dempsey, Derek J Leishman, Joanne L Leaney, Jules C Hancox, Harry J Witchel.   

Abstract

The HERG potassium channel might have a non-canonical drug binding site, distinct from the channel's inner cavity, that could be responsible for elements of closed-state pharmacological inhibition of the channel. The macrolide antibiotic erythromycin is a drug that may block unconventionally because of its size. Here we used whole-cell patch-clamp recording at 37 degrees C from heterologously expressed HERG channels in a mammalian cell line to show that erythromycin either produces a rapid open-state-dependent HERG channel inhibition, or components of both open-state-dependent and closed-state-dependent inhibition. Alanine-substitution of HERG's canonical determinants of blockade revealed that Y652 was not important as a molecular determinant of blockade, and that mutation of F656 resulted in only weak attenuation of inhibition. In computer models of the channel, erythromycin could make several direct contacts with F656, but not with Y652, in the open-state model, and erythromycin was unable to fit into a closed-state channel model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446155     DOI: 10.1016/j.bbrc.2006.01.008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.

Authors:  W J Crumb
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 2.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

3.  Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.

Authors:  W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-08

4.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

5.  Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels.

Authors:  Michael J Twiner; Gregory J Doucette; Andrew Rasky; Xi-Ping Huang; Bryan L Roth; Michael C Sanguinetti
Journal:  Chem Res Toxicol       Date:  2012-08-10       Impact factor: 3.739

6.  In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.

Authors:  Ehab Al-Moubarak; Mohsen Sharifi; Jules C Hancox
Journal:  Front Cardiovasc Med       Date:  2021-05-04

Review 7.  The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation.

Authors:  Barbara Wiśniowska; Sebastian Polak
Journal:  Curr Pharmacol Rep       Date:  2016-10-27

8.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04

9.  Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

Authors:  R S Duncan; M J McPate; J M Ridley; Z Gao; A F James; D J Leishman; J L Leaney; H J Witchel; J C Hancox
Journal:  Biochem Pharmacol       Date:  2007-05-03       Impact factor: 5.858

10.  Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition.

Authors:  Chunyun Du; Aziza El Harchi; Henggui Zhang; Jules C Hancox
Journal:  Physiol Rep       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.